University Medicine Greifswald
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases and Neoplasms
At University Medicine Greifswald, research in Innere Medizin C focuses on blood cancers and related malignancies, with studies aimed at improving outcomes for patients with aggressive lymphoma and nasopharyngeal carcinoma.
- Evaluating whether a new treatment combination can extend disease control in older adults with previously untreated diffuse large B-cell lymphoma.
- Assessing whether treatment can improve response rates in EBV-positive nasopharyngeal carcinoma so that radiotherapy intensity may be safely reduced.
The site’s clinical trials are centered on testing better cancer therapies and refining treatment strategies to balance effectiveness with long-term patient well-being.
Oncology with a focus on lymphoid malignancies
Clinical research at this hospital clinic is exploring new ways to treat complex B-cell lymphoma subtypes, including difficult-to-manage forms such as DLBCL and related high-grade variants.
- Testing whether adding an additional targeted therapy can improve progression-free survival in patients who are not eligible for standard full-intensity chemotherapy.
- Studying treatment response in a broad range of large B-cell lymphoma subtypes to support more effective care for these rare diseases.
This research reflects a strong interest in improving treatment effectiveness for hematologic cancers while adapting therapy to patient age and clinical needs.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 18 therapeutic areas and 15 of 188 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 187 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 42 by active trials.
- 1GPOH gGmbH6active
lock +41 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GPOH gGmbH6trials
lock +25 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Medicine Greifswald
lock Showing 1 of 113 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Visugromab in Patients with Cancer-associated Cachexia | CatalYm GmbH | Phase IV | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 188 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Etoposide | 15 | Unknown | 2014-03-27 | 2025-12-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.